Bharat Biotech had also said that following the WHO inspection, it was working on further improvements and upgrades to ensure that Covaxin production continues to meet the ever-increasing global regulatory requirements. (Representational image: AFP)
The two companies have amended their agreement to expand OcuGen’s exclusive territory to include commercialization of Covaxin in Mexico, they said in a joint statement.
- PTI New Delhi
- Last Update:April 18, 2022, 22:39 IST
- follow us on:
Biotechnology firms Ocugen and Bharat Biotech on Monday said they have agreed to include Mexico in their co-development, supply and commercialization agreement for the latter’s COVID-19 vaccine, Covaxin. The two companies have amended their agreement to expand OcuGen’s exclusive territory to include commercialization of Covaxin in Mexico, they said in a joint statement.
“This gives Ocugen Covaxin commercialization rights for the whole of North America,” it added. The license extension between Ocugen and Bharat Biotech regarding commercialization in Mexico includes a profit sharing structure similar to that of the US.
Ocugen Chairman, CEO and Co-Founder Shankar Musunuri said, “Covaxin is currently being reviewed by COFEPRIS (Comisin Federal para la Proteccin contra Riesgos Sanitarios) for emergency use among children aged 2 to 18 years. and Ocugen is ready to collaborate with the public health community to assist in their efforts.” Krishna Ella, Chairman and Managing Director, Bharat Biotech, said, “We are manufacturing Covaxin on a commercial scale in North America. The team fully supports Okugain in our effort to accelerate technology transfer activities towards the U.S.” Earlier this month, the World Health Organization (WHO) urged the United Nations to Confirmed the suspension of the supply of the vaccine through the U.S. procurement agencies and recommended the countries that received the vaccine to take appropriate action.WHO said the suspension was carried out by its Post Emergency Use Listing (EUL) inspection. It was in response to the result of Shan.
Bharat Biotech had also said that following the WHO inspection, it was working on further improvements and upgrades to ensure that Covaxin production continues to meet the ever-increasing global regulatory requirements. The company also announced that it is temporarily slowing production of its Covaxin at its manufacturing units in order to optimize facility, as it has already met its supply obligations to procurement agencies, and a reduction in demand. are supposed to.
read all Breaking News , today’s fresh news And IPL 2022 Live Updates Here.